The present disclosure concerns a combination comprising a plurality of proteotypic peptides for measuring, using mass spectrometry, the expression of at least two proteins in the PD-L1 axis. The combination comprises a synthetic standard lymphocyte specific kinase (LCK) peptide, a synthetic standard NT5E (CD73) peptide, a synthetic standard programmed cell death protein 1 (PD-1) peptide, a synthetic standard programmed death-ligand 1 (PD-1) peptide, a synthetic standard programmed death-ligand 2 (PD-L2) peptide and/or a synthetic standard zeta-chain-associated protein kinase 70 (ZAP70) peptide. The combination of synthetic standard peptides can be used in combination with affinity agents, such as antibodies, specific for synthetic standard peptides. The combination of the present disclosure can be used to tailor an appropriate therapeutic regimen or monitor the efficiency of a therapeutic regimen comprising checkpoint inhibitor modulating agents.

Biomarkers and methods for the treatment of non-small cell lung cancer (NSCLC). Biomarkers for patient selection and prognosis, and diagnostic kit for analyzing the biomarkers.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor and/or survival factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes a survival factor, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor and/or a different survival factor.

Compositions and methods for treating hemorrhagic shock, multiple organ failure resulting from hemorrhagic shock, and organ complications resultant therefrom such as acute respiratory distress syndrome.